A Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Cross-over Phase I Clinical Trial to Investigate the Effect of CKD-519 on 24-h Ambulatory Blood Pressure After Oral Administration in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2017
At a glance
- Drugs CKD 519 (Primary)
- Indications Dyslipidaemias
- Focus Pharmacodynamics
- Sponsors Chong Kun Dang
- 20 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.